NewAmsterdam Pharma Company NV

D

الأسعار متأخرة 15 دقيقة

القطاع: Healthcare

الصناعة: Biotechnology

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.